[go: up one dir, main page]

WO2010010566A1 - Improved process for the manufacture of ziprasidone - Google Patents

Improved process for the manufacture of ziprasidone Download PDF

Info

Publication number
WO2010010566A1
WO2010010566A1 PCT/IN2008/000469 IN2008000469W WO2010010566A1 WO 2010010566 A1 WO2010010566 A1 WO 2010010566A1 IN 2008000469 W IN2008000469 W IN 2008000469W WO 2010010566 A1 WO2010010566 A1 WO 2010010566A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
ziprasidone
derivative
iii
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2008/000469
Other languages
French (fr)
Inventor
Om Dutt Tyagi
Tushar Kumar Srivastava
Vasanth Kumar Nalam
Sadanand Nilkanth Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to PCT/IN2008/000469 priority Critical patent/WO2010010566A1/en
Publication of WO2010010566A1 publication Critical patent/WO2010010566A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Definitions

  • the present invention relates to an improved method for the manufacture of Ziprasidone of the formula (I), chemically known as 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyl)ethyl)- 6-chloro-l,3-dihydro-2H-indol-2-one and identified by the CAS registration number [146939-27-7], which is an antipsychotic agent used for the treatment of schizophrenia.
  • Ziprasidone of the formula (I) chemically known as 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyl)ethyl)- 6-chloro-l,3-dihydro-2H-indol-2-one and identified by the CAS registration number [146939-27-7], which is an antipsychotic agent used for the treatment of schizophrenia.
  • Ziprasidone of formula (I) is generically covered in the US 4,831,031 that discloses its synthesis by the reaction of 3-piperazinylbenzo[d]isothiazole of formula (II) (hereinafter, PBT) and 6-chloro-5-(2-chloroethyl)indolin-2-one of formula (III) (hereinafter, CEOI) in a polar organic solvent such as ethanol, dimethylformamide or methylisobutyl ketone; in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine or alkali metal base such as sodium carbonate, and in the further presence of catalytic amount of sodium iodide. The final product is purified by chromatography. This method suffers from the following disadvantages,
  • US 5,206,366 discloses and claims a process for making Ziprasidone (I) by reacting PBT free base and CEOI in water and in the presence of neutralizing agent sodium carbonate, at refluxing temperature for about 9 to 12 hours.
  • the ziprasidone free base is prepared by reacting PBT hydrochloride and CEOI by refluxing hydrochloride salt of (II) with (III) in water and in presence of a neutralizing agent sodium carbonate for about 8 to 16 hours.
  • WO 2005/040160 discloses and claims a process of similar coupling in various solvents that include water, alcohols, glycols, sulfolane and tolune, in presence of bases like sodium carbonate.
  • WO 2005/085240 discloses and claims similar coupling in water, without employing any base.
  • the object of the invention is to provide an improved method to manufacture Ziprasidone (I) without employing external bases and overcoming the short comings of te prior art.
  • present invention provides an improved method to manufacture Ziprasidone (I) by the coupling of free base piperazine derivative (II) with oxindole derivative of formula (III) by heating in a non-aqueous suspending liquid, for example, sulfolane, without the need of any external base and optionally in presence of a catalyst.
  • a non-aqueous suspending liquid for example, sulfolane
  • the coupling reaction of this instant invention is an equimolecular condensation reaction between an amine (piperezine derivative, a nitrogen containing organic base) and a chloroethyl oxindole derivative. During the condensation hydrochloric acid (HCl) is liberated which needs to be scavenged.
  • amine piperezine derivative, a nitrogen containing organic base
  • chloroethyl oxindole derivative a chloroethyl oxindole derivative
  • this instant invention provides a process wherein the piperazine derivative of formula (II) is used in a molar ratio excess to the oxindole derivative of formula (III).
  • the preferred molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1:1 and 2.5:1, more preferably between 1.2:1 and 2:1.
  • the excess quantity of the piperizine derivative (II) captures the HCl. Hence the reaction takes place even without the addition of any external inorganic or organic base.
  • the said coupling of the free base piperazine derivative (II) with oxindole derivative of formula (III) is effected by heating the mixture of (II) and (III) in a non-aqueous suspending liquid, for example, sulfolane, at a temperature in the range of 50° to 15O 0 C. The most preferred temperature is 80-90 0 C.
  • Alkali metal halides for example, sodium or potassium iodides, are optionally used in the reaction as a catalyst.
  • the process of the present invention results in a pure ziprasidone, which precipitates as a filterable solid mass.
  • the product may be purified by washing with acetone.
  • the ziprasidone obtained by the process of the present invention can be converted to its hydrochloride or other pharmaceutically acceptable salts by known methods.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

An improved method for preparing a compound of formula (I): which comprises of coupling the piperazine derivative of formula (II) with oxindole derivative of formula (III): by heating in a non-aqueous medium, in the absence of an external base and optionally in presence of a catalyst.

Description

IMPROVED PROCESS FOR THE MANUFACTURE OF ZIPRASIDONE
FIELD OF INVENTION
The present invention relates to an improved method for the manufacture of Ziprasidone of the formula (I), chemically known as 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyl)ethyl)- 6-chloro-l,3-dihydro-2H-indol-2-one and identified by the CAS registration number [146939-27-7], which is an antipsychotic agent used for the treatment of schizophrenia.
BACKGROUND OF THE INVENTION
Ziprasidone of formula (I) is generically covered in the US 4,831,031 that discloses its synthesis by the reaction of 3-piperazinylbenzo[d]isothiazole of formula (II) (hereinafter, PBT) and 6-chloro-5-(2-chloroethyl)indolin-2-one of formula (III) (hereinafter, CEOI) in a polar organic solvent such as ethanol, dimethylformamide or methylisobutyl ketone; in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine or alkali metal base such as sodium carbonate, and in the further presence of catalytic amount of sodium iodide. The final product is purified by chromatography. This method suffers from the following disadvantages,
1) Longer reaction time of 24 to 72 hours,
2) Formation of considerable quantities of by products,
3) Special purification techniques like chromatography and,
Moreover, when practiced in the laboratory, the process of US 4,831,031 resulted in low yield from 14 to 22%.
US 5,206,366 discloses and claims a process for making Ziprasidone (I) by reacting PBT free base and CEOI in water and in the presence of neutralizing agent sodium carbonate, at refluxing temperature for about 9 to 12 hours.
US 5,338,846, which is a continuation-in-part of US 5,206,366, discloses and claims a process for the preparation of hydrochloride salt of Ziprasidone (I). The ziprasidone free base is prepared by reacting PBT hydrochloride and CEOI by refluxing hydrochloride salt of (II) with (III) in water and in presence of a neutralizing agent sodium carbonate for about 8 to 16 hours.
WO 2005/040160 discloses and claims a process of similar coupling in various solvents that include water, alcohols, glycols, sulfolane and tolune, in presence of bases like sodium carbonate.
WO 2005/085240 discloses and claims similar coupling in water, without employing any base.
The above-mentioned methods have the following disadvantages,
1) Require tedious purification procedures such as chromatographic separation.
2) The presence of base, as per the prior art disclosed methods discussed hereinbefore, increases impurity level of the reaction mass so that it becomes a dark, thick gummy mass which does not allow precipitation of the product as a filterable solid mass. The residue needs further tedious purification that increases the cost of the process and decreases process efficiency.
Surprisingly, the present inventors have found that the above coupling reaction to manufacture Ziprasidone (I) can be effectively carried out by mixing 3- piperazinylbenzo[d]isothiazole (II) and 6-chloro-5-(2-chloroethyl)indolin-2-one (III) and heating in the presence of catalytic amount of alkali metal halide such as potassium iodide in a non-aqueous medium, for instance sulfolane, without employing such external bases, thus overcoming the limitations of the prior art discussed hereinbefore.
OBJECTS OF THE INVENTION
Thus the object of the invention is to provide an improved method to manufacture Ziprasidone (I) without employing external bases and overcoming the short comings of te prior art. SUMMARY OF THE INVENTION
Thus present invention provides an improved method to manufacture Ziprasidone (I) by the coupling of free base piperazine derivative (II) with oxindole derivative of formula (III) by heating in a non-aqueous suspending liquid, for example, sulfolane, without the need of any external base and optionally in presence of a catalyst.
Figure imgf000004_0001
(H) (in) (I)
DETAILED DESCRIPTION OF THE INVENTION The coupling reaction of this instant invention is an equimolecular condensation reaction between an amine (piperezine derivative, a nitrogen containing organic base) and a chloroethyl oxindole derivative. During the condensation hydrochloric acid (HCl) is liberated which needs to be scavenged.
Accordingly, this instant invention provides a process wherein the piperazine derivative of formula (II) is used in a molar ratio excess to the oxindole derivative of formula (III). The preferred molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1:1 and 2.5:1, more preferably between 1.2:1 and 2:1. The excess quantity of the piperizine derivative (II) captures the HCl. Hence the reaction takes place even without the addition of any external inorganic or organic base.
The said coupling of the free base piperazine derivative (II) with oxindole derivative of formula (III) is effected by heating the mixture of (II) and (III) in a non-aqueous suspending liquid, for example, sulfolane, at a temperature in the range of 50° to 15O0C. The most preferred temperature is 80-900C.
Alkali metal halides, for example, sodium or potassium iodides, are optionally used in the reaction as a catalyst.
The process of the present invention results in a pure ziprasidone, which precipitates as a filterable solid mass. The product may be purified by washing with acetone.
The ziprasidone obtained by the process of the present invention can be converted to its hydrochloride or other pharmaceutically acceptable salts by known methods.
The invention is further illustrated by the following non-limiting example.
Example 1
Preparation of 5-(2-(4-(l,2-benzisothiazol-3-yl)-l-piperazinyI)ethyI)-6-chIoro-l,3- dihydro-2H-indol-2-one (Ziprasidone)
To a solution of sulfolane (69 ml), 5-(2-chloroethyl)-6-chloro-oxindole (23 g, 0.1 mole) and l-(l,2-benzothiozol-3-yl) piperazine (43.7 g, 0.2 mole), KI (1.15 g, 5%) was added at 30- 350C. The mixture was slowly heated under stirring to 80-900C over 60-90min. The mixture was stirred for 24-26 hr, after completion of the reaction as monitored by HPLC, the reaction mass was cooled to room temperature. Added water (230 ml) and stirred the reaction mass for 60 min. The solid was filtered and washed with water (115 ml). Suck dry the solid for 2 hr. The wet solid was stirred with acetone (230 ml) for 60 min. Filtered the solid with acetone (50 ml) dried the solid under vacuum at 4O0C for 4-5 hr. Yield: 24 g (57%) Purity by HPLC: - 90%

Claims

1. A process for preparing the compound of formula (I)
Figure imgf000006_0001
comprising of reacting a piperazine derivative of formula (II) and an oxindole derivative of formula (III),
Figure imgf000006_0002
(H) (III)
in a non-aqueous suspending liquid, in the absence of an external base, optionally in presence of a catalyst.
2. The process as claimed in claim 1, wherein the molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1:1 and 2.5:1.
3. The process as claimed in claim 1, wherein the molar ratio of the piperazine derivative of formula (II) and the oxindole derivative of formula (III) ranges between 1.2:1 and 2:1.
4. The process as claimed in any of the preceding claims wherein the non-aqueous suspending liquid is sulfolane.
5. The process as claimed in any of the preceding claims wherein the catalyst is selected from sodium iodide and potassium iodide.
6. The process as claimed in any of the preceding claims wherein the temperature of the reaction is in the range of 50° to 15O0C.
PCT/IN2008/000469 2008-07-25 2008-07-25 Improved process for the manufacture of ziprasidone Ceased WO2010010566A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000469 WO2010010566A1 (en) 2008-07-25 2008-07-25 Improved process for the manufacture of ziprasidone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000469 WO2010010566A1 (en) 2008-07-25 2008-07-25 Improved process for the manufacture of ziprasidone

Publications (1)

Publication Number Publication Date
WO2010010566A1 true WO2010010566A1 (en) 2010-01-28

Family

ID=40262306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000469 Ceased WO2010010566A1 (en) 2008-07-25 2008-07-25 Improved process for the manufacture of ziprasidone

Country Status (1)

Country Link
WO (1) WO2010010566A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005085240A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
WO2006011157A2 (en) * 2004-06-18 2006-02-02 Lupin Limited Methods for the preparation of aryl piperazinyl-heterocyclic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005085240A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
WO2006011157A2 (en) * 2004-06-18 2006-02-02 Lupin Limited Methods for the preparation of aryl piperazinyl-heterocyclic compounds

Similar Documents

Publication Publication Date Title
US8993778B2 (en) Process for manufacture of telmisartan
WO2012068441A2 (en) Intedanib salts and solid state forms thereof
JP5016575B2 (en) A novel synthesis of strontium ranelate and its hydrates
US20140221652A1 (en) Improved process for preparation of imatinib and its mesylate salt
US20050143396A1 (en) Novel crystalline forms of ziprasidone hydrochloride
KR20140128926A (en) Process for the production of bendamustine alkyl ester, bendamustine, and derivatives thereof
CN101939314A (en) Polymorphs of 3-pyrrole-substituted 2-indolinones
CZ296543B6 (en) 1,2,4-Trisubstituted imidazole compound and quaternary salt of 1,2,3,4-tetrasubstituted imidazole compound
CN111757870A (en) Method for synthesizing sulfentrazone
WO2010010566A1 (en) Improved process for the manufacture of ziprasidone
EP1026163B1 (en) Process for producing substituted alkylamines or salts thereof
CN101171251A (en) The preparation method of aztreonam
US7601832B2 (en) Process for making aztreonam
CN101245078B (en) Benzathine salt of ceftiofur, preparation method and application thereof
EP1845088B1 (en) An improved process for the preparation of aripipirazole
KR102702677B1 (en) Process for Preparation of Fimasartan and Intermediate for Preparing the Same
JP6210599B2 (en) Process for producing 4-methyl-6 (1-methylbenzimidazol-2-yl) -2-n-propyl-1H-benzimidazole
US7087611B2 (en) Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride)
US8129536B2 (en) Method for the purification of lansoprazole
US7728136B2 (en) Method for the preparation of aryl piperazinyl-heterocyclic compounds
US20080214816A1 (en) Process for Preparing Ziprasidone
KR100351743B1 (en) Process for preparation of the n,n-dicyclohexyl-2-benzothiazole sulfenamide
US20080312254A1 (en) Process for the Preparation of Ziprasidone
WO2011080749A1 (en) Process for purification of ziprasidone
US20070078143A1 (en) Method for preparing Ziprasidone monohydrochloride-hydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08789920

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08789920

Country of ref document: EP

Kind code of ref document: A1